MangoceuticalsMGRX
MGRX
About: Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
150% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 4
107% more capital invested
Capital invested by funds: $151K [Q2] → $313K (+$162K) [Q3]
100% more funds holding
Funds holding: 6 [Q2] → 12 (+6) [Q3]
2.5% more ownership
Funds ownership: 1.99% [Q2] → 4.49% (+2.5%) [Q3]
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Research analyst outlook
We haven’t received any recent analyst ratings for MGRX.
Financial journalist opinion
Neutral
GlobeNewsWire
1 day ago
Mangoceuticals, Inc. Completes Acquisition of Mushroom-Based Wellness and Innovations Patent
Dallas, TX, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform, today announced the acquisition of patent number WO 2023/086647 PCT/US2022/049857, for mushroom-derived compositions and methods of treatment. This new addition to MangoRx's intellectual property portfolio highlights the Company's commitment to innovative solutions that support holistic health and wellness.
Neutral
GlobeNewsWire
1 month ago
MangoRx Responds to and Refutes Recent Claims Made by Eli Lilly
Dallas, Texas, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform learned earlier this morning that Eli Lilly has made certain public claims alleging, and has stated that it has filed a lawsuit against MangoRx claiming, that MangoRx improperly copied its weight-loss medicine, Zepbound and Mounjaro. MangoRx strongly refutes any and all claims made by Eli Lilly regarding the sale of compounded tirzepatide. MangoRx believes it has strong arguments against Eli Lilly's claims and intends to vigorously defend itself in this matter.
Neutral
Newsfile Corp
2 months ago
Mangoceuticals, Inc. Announces Participation at the Centurion One Capital 2nd Annual Bahamas Summit 2024
Dallas, Texas--(Newsfile Corp. - October 18, 2024) - Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform,, is pleased to announce it will be presenting at the Centurion One Capital 2nd Annual Bahamas Summit, which will be taking place at the exclusive Rosewood Baha Mar Hotel from Tuesday, October 22nd to Wednesday, October 23rd, 2024, in Nassau, Bahamas. Jacob Cohen, Founder and CEO, is scheduled to present on Wednesday, October 23rd at 11:10 EDT.
Positive
Benzinga
2 months ago
Top 3 Risk Off Stocks Which Could Rescue Your Portfolio This Quarter
The most oversold stocks in the consumer staples sector presents an opportunity to buy into undervalued companies.
Neutral
GlobeNewsWire
2 months ago
MANGOCEUTICALS, INC. ANNOUNCES 1-FOR 15 REVERSE STOCK SPLIT AS PART OF NASDAQ COMPLIANCE PLAN
DALLAS, TX, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-15 (the “Reverse Stock Split”). The Reverse Stock Split will become effective on October 16, 2024 at 12:01 a.m. Eastern Time (the “Effective Time”), with shares expected to begin trading on the Nasdaq Capital Market, on a split-adjusted basis, at market open on October 16, 2024. In connection with the Reverse Stock Split, every fifteen shares of the Company's common stock issued and outstanding as of the Effective Time will be automatically converted into one share of the Company's common stock. No change will be made to the trading symbol for the Company's shares of common stock, “MGRX”, in connection with the reverse split.
Neutral
GlobeNewsWire
2 months ago
MangoRx Introduces Oral Tirzepatide GLP-1 Receptor Agonist for Advanced Weight Loss Solutions
Dallas, Texas, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform, announces the release of its latest innovation, “TRIM,” a compounded, oral dissolvable Tirzepatide tablet. Available for purchase at $399 per month, this new product offers patients an advanced and convenient alternative to injectable therapies.
Neutral
GlobeNewsWire
2 months ago
MangoRx Addresses $49.3 Billion Global GLP-1 Market With Launch of Oral Semaglutide for Advanced Weight Loss Treatment
MangoRx aims to capitalize on growing demand for GLP-1 treatments to drive revenue growth and expand market share in the weight loss category
Neutral
GlobeNewsWire
4 months ago
MangoRx Reports 1,685% Increase in Shareholders' Equity From December 31, 2023, to $13.8MM, and 56% Increase in Year-Over-Year Revenue for First Half of 2024
Dallas, Texas, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“ MangoRx ” or the “Company”), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, today announced its financial results for the three and six months ending June 30, 2024, showing a significant growth in both shareholder's equity and gross revenues.
Neutral
GlobeNewsWire
4 months ago
MangoRx Completes Migration to DEA-Approved Telemedicine Platform, Accelerating Timeline of Oral Dissolvable GLP-1 Weight Loss Treatments Featuring Semaglutide and Tirzepatide
Dallas, Texas, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the areas of erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, proudly announces the successful migration to its newly developed DEA-approved telemedicine operating system. This milestone marks a significant advancement in MangoRx's capabilities, reinforcing its commitment to innovation and superior patient care.
Neutral
Accesswire
4 months ago
MangoRx Receives Request for Proposal (RFP) From ISFLST for New Male Enhancement Product Exclusive for the Asian Market
Dallas, TX Based Men's Health Telemedicine Company Announces Successful Participation in Beijing Exhibit DALLAS, TX / ACCESSWIRE / August 8, 2024 / Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a leader in developing, marketing, and selling a variety of men's health and wellness products, is pleased to announce the receipt of its first Request for Proposal (RFP) from its distributor, the International Society of Frontier Life Sciences and Technology (ISFLST). This RFP focuses on the formulation, production, and packaging of a new male enhancement non-prescription product, intended to be introduced and sold in the Chinese market as a natural solution for men's health.
Charts implemented using Lightweight Charts™